PMID- 33298649
OWN - NLM
STAT- MEDLINE
DCOM- 20210202
LR  - 20210202
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 61
IP  - 11
DP  - 2020
TI  - [Therapy-related acute promyelocytic leukemia with complex karyotype accompanied 
      by cryptic PML/RARA on chromosome 15 by metaphase FISH].
PG  - 1577-1583
LID - 10.11406/rinketsu.61.1577 [doi]
AB  - A 53-year-old male presented with pancytopenia for 13 months. He had a past 
      history of follicular lymphoma and hypopharyngeal cancer, which was treated via 
      chemotherapy and radiotherapy. Bone marrow aspiration biopsy of the patient 
      revealed a hypocellular marrow with 32% of hypergranular blasts without Auer 
      bodies. There were also erythroid and megakaryocytic dysplasia in the bone 
      marrow. Although the PML/RARA transcript was detected by fluorescence in situ 
      hybridization (FISH) and reverse transcription polymerase chain reaction 
      (RT-PCR), the G-banding karyotype analysis showed a complex karyotype without t 
      (15;17). The PML/RARA fusion signal was identified on chromosome 15 by metaphase 
      FISH. The patient was diagnosed of therapy-related acute promyelocytic leukemia 
      (t-APL) with cryptic PML/RARA. He successfully attained molecular complete 
      remission with all-trans retinoic acid (ATRA) and two courses of arsenic trioxide 
      (ATO). He was subsequently administered nivolumab without ATRA maintenance 
      therapy because of a progressing metastasis of a hypopharyngeal cancer to the 
      lung. The patient had a relapse of t-APL following nine courses of nivolumab, 8 
      months after ending consolidation therapy with ATO. Reinduction therapy with ATRA 
      was not effective for the relapsed t-APL that was accompanied by del (5q) and 
      monosomy 7. Little has been previously reported on t-APL with cryptic PML/RARA. 
      Therefore, the clinical course of this patient may provide useful insights about 
      the characteristics of t-APL with cryptic PML/RARA.
FAU - Kashima, Emiko
AU  - Kashima E
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
AD  - Department of Hematology, Suzuka Kaisei Hospital.
FAU - Sugimoto, Yuka
AU  - Sugimoto Y
AD  - Department of Community Hematology, Mie University Faculty of Medicine.
AD  - Internal Medicine, Takeuchi Hospital.
FAU - Nato, Yuma
AU  - Nato Y
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
AD  - Department of Hematology, Yokkaichi Municipal Hospital.
FAU - Ino, Kazuko
AU  - Ino K
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
FAU - Tawara, Isao
AU  - Tawara I
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
FAU - Masuya, Masahiro
AU  - Masuya M
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
FAU - Katayama, Naoyuki
AU  - Katayama N
AD  - Department of Hematology and Oncology, Mie University Graduate School of 
      Medicine.
LA  - jpn
PT  - Case Reports
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 5688UTC01R (Tretinoin)
SB  - IM
MH  - Chromosomes, Human, Pair 15/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotype
MH  - *Leukemia, Promyelocytic, Acute/drug therapy/genetics
MH  - Male
MH  - Metaphase
MH  - Middle Aged
MH  - Oncogene Proteins, Fusion/genetics
MH  - Tretinoin
OTO - NOTNLM
OT  - Cryptic PML/RARA
OT  - Metaphase FISH
OT  - Myelodysplasia
OT  - Therapy-related APL
EDAT- 2020/12/11 06:00
MHDA- 2021/02/03 06:00
CRDT- 2020/12/10 05:42
PHST- 2020/12/10 05:42 [entrez]
PHST- 2020/12/11 06:00 [pubmed]
PHST- 2021/02/03 06:00 [medline]
AID - 10.11406/rinketsu.61.1577 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2020;61(11):1577-1583. doi: 10.11406/rinketsu.61.1577.